Evidence map›Paper›PMID 39846486›Full record

ArticleBiotechnology progress

A method for facile production of variable lymphocyte receptors using SHuffle Escherichia coli.

Elizabeth A Appelt, James B Thoden, Candis Dancy, Hannah D Bachmeier, Seth A Gehrke, Melanie A Staffenson, Ivan Rayment, Moriah E Katt, Hazel M Holden, Eric V Shusta

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elizabeth A AppeltDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.
James B ThodenDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Candis DancyDepartment of Chemical and Biomedical Engineering, West Virginia University, Morgantown, West Virginia, USA.
Hannah D BachmeierDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Seth A GehrkeDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Melanie A StaffensonDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ivan RaymentDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Moriah E KattDepartment of Chemical and Biomedical Engineering, West Virginia University, Morgantown, West Virginia, USA.
Hazel M HoldenDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Eric V ShustaDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-4297-0158

Funding

Biotechnology Training ProgramT32GM135066 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI SCOTT M. COYLE, BRIAN G FOX · 2020 to 2026
$7.0M
New Human Antibodies for CNS Drug DeliveryR01NS118028 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI SHUSTA, ERIC V · 2021 to 2025
$1.9M
Identification of Lamprey Antibodies Capable of Noninvasive Brain Drug DeliveryR01NS099158 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI SHUSTA, ERIC V · 2017 to 2021
$1.7M
NIGMS NIH HHS T32 GM135066NIH HHS GM135066NIH HHS NS099158NIH HHS NS118028NINDS NIH HHS R01 NS099158NINDS NIH HHS R01 NS118028
6 · The paper itself

Abstract

Variable lymphocyte receptors (VLRs) are the antigen receptors of jawless vertebrates such as lamprey. VLRs are of growing biotechnological interest for their ability to bind certain antigenic targets with higher affinity than traditional immunoglobulins. However, VLRs are disulfide-bonded proteins that are often challenging to produce requiring genetic modifications, fusion partners, non-scalable host cell lines or inclusion body formation and refolding. As a potential VLR expression platform option, the SHuffle Escherichia coli strain has been genetically altered to allow cytoplasmic disulfide bond formation by mutations to thioredoxin reductase (trxB) and glutathione reductase (gor) to create an oxidative cytoplasm. Furthermore, the SHuffle strain expresses disulfide bond isomerase DsbC in the cytoplasm to promote correct disulfide bond pairing. Here, we demonstrate that the SHuffle strain can produce high yield VLRs with titers ranging from 2 to 32 mg of VLR per liter of SHuffle culture. Three VLRs (P1C10, RBC36, VLRA.R2.1) were expressed in SHuffle E. coli and the products were compared directly to those generated using the Rosetta E. coli strain. All VLRs were validated for correct sequence, purity, and activity. For all VLRs, SHuffle E. coli produced 2-9 times more soluble VLRs than Rosetta E. coli. Furthermore, the soluble protein fraction was 2-6 times greater in SHuffle E. coli than Rosetta E. coli for all VLRs. Overall, these results suggest that the E. coli SHuffle strain is a convenient and effective expression system for producing large amounts of VLRs.

Indexed as

Escherichia coliReceptors, AntigenAnimalsLampreysRecombinant ProteinsReceptors, AntigenRecombinant Proteinsbacterial protein expressiondisulfide bondsSHuffle E. Colivariable lymphocyte receptors

Identifiers

PMID39846486
PMCPMC12171313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.